AdAlta Ltd (ASX: 1AD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

AdAlta Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $23.17 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 297.01 million
Earnings per share -0.024
Dividend per share N/A
Year To Date Return -8.75%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

AdAlta Ltd (ASX: 1AD)
Latest News

woman in lab coat conducting testing representing biotech
Share Market News

AdAlta (ASX:1AD) share price rockets 31% on United States FDA update

The AdAlta Ltd (ASX:1AD) share price is rocketing today following the positive news on its drug trials. In mid-morning trade, …

Read more »

1AD ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About AdAlta Ltd

AdAlta Ltd is engaged in drug discovery and development company developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal.

1AD Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
28 Jan 2022 $0.08 $0.01 13.70% 15,491 $0.07 $0.08 $0.07
27 Jan 2022 $0.07 $0.00 0.00% 530,661 $0.08 $0.08 $0.07
25 Jan 2022 $0.08 $0.00 0.00% 588,915 $0.08 $0.08 $0.08
24 Jan 2022 $0.08 $0.00 0.00% 156,202 $0.08 $0.08 $0.08
21 Jan 2022 $0.08 $0.00 0.00% 369,780 $0.08 $0.08 $0.08
20 Jan 2022 $0.08 $0.00 0.00% 66,400 $0.08 $0.08 $0.08
19 Jan 2022 $0.08 $0.00 0.00% 225,670 $0.08 $0.08 $0.08
18 Jan 2022 $0.08 $0.00 0.00% 191,310 $0.08 $0.08 $0.08
17 Jan 2022 $0.08 $0.00 0.00% 30,913 $0.08 $0.08 $0.08
14 Jan 2022 $0.08 $0.00 0.00% 196,352 $0.08 $0.08 $0.08
13 Jan 2022 $0.08 $0.00 0.00% 480,818 $0.08 $0.08 $0.08
12 Jan 2022 $0.08 $0.00 0.00% 145,287 $0.08 $0.08 $0.08
11 Jan 2022 $0.08 $0.00 0.00% 151,200 $0.08 $0.08 $0.08
10 Jan 2022 $0.08 $-0.01 -11.76% 802,860 $0.09 $0.09 $0.08
07 Jan 2022 $0.09 $0.00 0.00% 403,025 $0.08 $0.09 $0.08
06 Jan 2022 $0.08 $0.00 0.00% 47,913 $0.08 $0.08 $0.08
05 Jan 2022 $0.08 $0.00 0.00% 184,005 $0.08 $0.08 $0.08
04 Jan 2022 $0.08 $0.00 0.00% 94,178 $0.08 $0.08 $0.08

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
29 Nov 2021 David Fuller Issued 1 $98,400
Issue of options.
29 Nov 2021 Paul MacLeman Issued 3 $250,510
Issue of options.
29 Nov 2021 Timothy Oldham Issued 1 $98,400
Issue of options.
29 Nov 2021 Robert Peach Issued 1 $98,400
Issue of options.
26 Oct 2021 Timothy Oldham Buy 235 $19,991
On-market trade.
30 Jun 2021 Robert Peach Expiry 481 $60,166
Options expired.
30 Jun 2021 James Williams Expiry 66 $8,333
Options expired.
30 Jun 2021 Elizabeth (Liddy) McCall Expiry 16 $2,083
Options expired.
30 Jun 2021 Paul MacLeman Expiry 16 $2,083
Options expired.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr David Fuller Non-Executive Director Jul 2020
Mr Fuller has over 30 years' experience in pre-clinical, clinical development, medical and regulatory affairs with specialisations in early phase development and oncology. He has led five product approvals in the United States (US) and European Union (EU) for orphan and major market products, together with multiple Regulatory Agency (US/ EU) interactions including Investigational New Drug (IND) applications. David has designed and executed multiple Phase I - III studies in US, EU and Asia across multiple therapeutic areas. He is currently Chief Medical Officer for ASX listed Race Oncology and is also a Non-Executive Director at EpiAxis Therapeutics Pty Ltd. Previously he was Senior Vice President, Oncology, Syneos Health, a Non-Executive Director of Linear Clinical Research Ltd - a Perth based clinical trials facility - and a former Chair of Dimerix Ltd (ASX:DXB).
Ms Elizabeth (Liddy) McCall Non-Executive Director Oct 2010
Ms McCall is co-founder of 3 biotechnology companies successfully achieving 3 FDA drug registrations and 1 FDA/ CE Mark medical device approval. She is an inventor on patents granted in major jurisdictions translating novel G-protein coupled pharmacology into a therapeutic drug treatment currently in multiple Phase 3 clinical trials. Ms McCall co-founded IIF venture capital fund, Yuuwa Capital LP, which is responsible for a portfolio of 6 companies commercializing biotechnology and IT innovation. Ms McCall has over 25 years of experience in senior Board and management roles including iCeutica Inc group (acquired in 2011), Dimerix Bioscience Pty Ltd (now Dimerix Limited ASX:DXB), AdAlta Limited (ASX:1AD) and iCetana Pty Ltd (now iCetana Limited ASX:ICE). Ms McCall was an Associate Director in the Corporate Advisory Group of Macquarie Bank and prior to that worked as a lawyer with a leading Australian law firm. She has qualifications in law and finance. Ms McCall is a Non-Executive Director of the notfor-profit Ear Science Institute Australia and also of Argenica Therapeutics Ltd (ASX:AGN), Agworld Pty Ltd, Nexgen Plants Pty Ltd and The Tailor Made Spirits Company Limited.
Dr Paul MacLeman Executive ChairmanExecutive Director Apr 2015
Dr MacLeman has over 25 years' experience across all phases of the life sciences sector. With a career-spanning veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance, Dr MacLeman has expertise in capital raising, business development, technology commercialisation and sales & marketing globally. Dr MacLeman has launched products using both in-house and outsourced sales staff in Australia and the US. He has founded life sciences start-ups in the biologics area and worked in investment banking focusing on the analysis and financing of technology companies. Dr MacLeman has previously served as Chairman, Director or Managing Director/CEO of several VC funded, ASX, NASDAQ, CSE and TSX listed companies. Dr MacLeman is currently Executive Chairman of Island Pharmaceuticals Limited, Chairman of SuperTrans Medical Limited and nonexecutive director of Upkara Inc. and Upkara Asia Pacific Pty Ltd. Dr MacLeman Chairs the Industry Review Committee for the Pharmaceutical Manufacturing National Training Package for the AISC. He is an advisor to PharmaVentures (Oxford, UK) and Mind Medicine. Dr MacLeman also serves on a number of other NFP and government advisory groups.
Dr James Howard Williams Alternate Director Oct 2010
Mr Williams is a co-founder and Investment Director of Yuuwa Capital LP, a venture capital firm based in Western Australia. Prior to Yuuwa Capital, he was Managing Director of two medical device companies, ASX-listed Resonance Health Ltd and Argus Biomedical Pty Ltd, both of which secured regulatory approvals under his leadership. He conceived, co-founded and is a former CTO and Director of iCeutica, Inc., a clinical stage nano drug delivery company. iCeutica was acquired by Philadelphia-based Iroko Pharmaceuticals in 2011. Iroko received FDA approval for the first three iCeutica formulations between 2013 and 2015. Mr Williams is Chairman of ASX-listed clinical stage drug discovery and development company Dimerix Ltd (ASX:DXB) and Director of Yuuwa investee company PolyActiva Pty Ltd. He is a member of the "Panel of Experts" for the University of Western Australia's Pathfinder Fund and a member of the Australian Federal Government's Entrepreneur Program Committee.
Dr Timothy Oldham Managing DirectorChief Executive Officer Oct 2019
Mr Oldham has almost 20 years of life sciences business development, alliance management, portfolio and product development, and commercialisation experience in Europe, Asia and Australia, with a particular focus on biologics, cell and gene therapies and pharmaceutical product. Immediately prior to this, he was Executive Leader of Tijan Ventures, an advisory business focussed on growing life sciences companies through strategic advisory and interim CEO, executive and non-executive leadership services, with a particular focus on biologics, cell and gene therapies and immunotherapy. Previous roles include CEO and Managing Director of Cell Therapies Pty Ltd, a leading contract manufacturer and distributor cellular therapies in Asia Pacific, President of Asia Pacific for Hospira, Inc., and a variety of senior management roles with Mayne Pharma Ltd prior to its acquisition by Hospira. Prior to this, Mr Oldham was an engagement manager with McKinsey & Company. Industry leadership roles include currently serving as a Director of BioMelbourne Network Inc and terms as Chair of the European Generic Medicines Association Biosimilars and Biotechnology Committee, a Director of the Alliance for Regenerative Medicine and a Director of the Generic Medicines Industry Association. He is a Non-executive Director at Acrux Ltd (ASX:ACR).
Dr Robert Peach Non-Executive Director Nov 2016
Mr Peach has 30 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry. In 2009 he co-founded Receptos, becoming Chief Scientific Officer and raising US$59M in venture capital and US$800M in an IPO and three subsequent follow-on offerings. In August 2015 Receptos was acquired by Celgene for $7.8B. He held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol- Myers Squibb, supporting inlicensing, acquisition and venture investments. His drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 4 registered drugs. He currently serves on the Board of Directors of Amplia Therapeutics, Rekover Therapeutics and is a Scientific Advisory Board member of Eclipse Bioinnovations. Robert is the co-author of 75 scientific publications and book chapters, and 17 patents
Mr Cameron Jones Chief Financial OfficerCompany Secretary May 2017
-
Cameron Jones Chief Financial OfficerCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Yuuwa Capital Lp 54,059,848 22.05%
HSBC Custody Nominees (Australia) Limited 28,993,114 11.83%
Meurs Holdings Pty Ltd - P&M Meurs Superannuation A/C 17,887,693 7.30%
Radiata Super Pty Ltd - R & E Sypkes Family Sf A/C 7,689,999 3.14%
Sacavic Pty Ltd - Morris Super Fund A/C 4,444,407 1.81%
Citycastle Pty Ltd 4,302,320 1.75%
La Trobe University 3,041,330 1.24%
Jagen Pty Ltd 2,500,000 1.02%
National Nominees Limited 2,101,000 0.86%
Mr Robin Beaumont & Ms Helen Shingler 2,075,000 0.85%
Skiptan Pty Ltd - P&M Meurs Family A/C 2,072,000 0.85%
Citicorp Nominees Pty Limited 2,001,388 0.82%
Bauldia Pty Ltd - Bonaventure Super Fund A/C 1,825,409 0.74%
Scintilla Strategic Investments Limited 1,424,972 0.58%
Mrs Gwen Murray Pfleger - Pfleger Family A/C 1,395,000 0.57%
Mr Alistair David Strong 1,300,000 0.53%
Robert Peach 1,295,999 0.53%
Bare Super Pty Ltd - Ballard Read Sf A/C 1,277,358 0.52%
Rui Long International Pty Ltd - Rui Long Family A/C 1,200,000 0.49%
Mr Iain Ross 1,150,000 0.47%

Profile

since

Note